All In Biotech

Drug Trial Radar · NCT05054114

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19

Last checked: Nov 20, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

630

Actual

Start

Dec 21, 2020

Primary completion

May 25, 2021

Study completion Sep 2, 2021

Sponsor

Lead sponsor
SPP Pharmaclon Ltd.Industry
Sponsor type
Industry
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.

Conditions

  • COVID-19 Respiratory Infection
  • Acute Respiratory Disease

Interventions

  • Interferon gamma human recombinant (IFN-G)Drug

    nasal form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Patients With Acute Respiratory Viral Infections, Including COVID-19, at the End of the Prophylactic PeriodTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.